HC5 Stock Chart & Stats
€14.69
€0.50(2.60%)
At close: 4:00 PM EST
€14.69
€0.50(2.60%)
Day’s Range― - ―
52-Week Range€13.30 - €19.29
Previous CloseN/A
Volume0.00
Average Volume (3M)105.00
Market Cap
€13.46B
Enterprise Value€22.92B
Total Cash (Recent Filing)€1.17B
Total Debt (Recent Filing)€10.71B
Price to Earnings (P/E)69.0
Beta0.28
Next Earnings
Aug 04, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.32
Shares Outstanding689,419,700
10 Day Avg. Volume0
30 Day Avg. Volume105
Financial Highlights & Ratios
PEG Ratio-2.23
Price to Book (P/B)1.49
Price to Sales (P/S)3.97
P/FCF Ratio8.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.12Price Target Upside30.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)0.26
Revenue Forecast (FY)€2.58B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistently positive operating cash flow and FCF (TTM > $1.1B) underpin durable dividend coverage, fund development and acquisitions, and enable share repurchases. This steady cash generation provides a structural buffer versus cyclical rent timing and supports long-term capital allocation.
Outpatient Medical And Senior Housing FundamentalsHigh occupancy, strong retention and positive re-leasing spreads in outpatient assets reflect resilient demand for medical-office space. Senior housing outperformance and operating strength diversify cash flows away from cyclical lab markets, improving portfolio stability and predictable rental income over time.
Janus IPO And Disciplined Capital RecyclingMajority ownership of the high-growth Janus Living platform creates a sizable monetization option and liquidity source. Management’s track record of recaps, JV exits and a $100M buyback shows disciplined recycling of capital into accretive acquisitions and shareholder returns, enhancing long-term value creation.
Bears Say
Elevated LeverageA materially leveraged balance sheet (debt > equity; net debt/EBITDA ~5.4x) limits financial flexibility, increases sensitivity to higher rates, and constrains the ability to pursue opportunistic acquisitions or absorb asset-level shocks, making capital allocation decisions more constrained over the medium term.
Life-science Vacancy And Lab Rent PressureSub-80% life-science occupancy, meaningful near-term expirations and softened lab re-leasing spreads indicate structural headwinds in lab submarkets. Prolonged vacancy or weaker rents could depress cash flow and delay expected life-science earnings upside, pressuring portfolio growth assumptions.
Refinancing And Interest-rate HeadwindsNear-term maturities and higher expected interest costs raise refinancing risk and reduce FFO growth potential. In a higher-rate environment, elevated debt levels amplify the earnings drag from refinancing, limiting free cash flow available for development, acquisitions, or additional buybacks over the medium term.
HC5 FAQ
What was Healthpeak Properties, Inc.’s price range in the past 12 months?
Healthpeak Properties, Inc. lowest stock price was €13.30 and its highest was €19.29 in the past 12 months.
What is Healthpeak Properties, Inc.’s market cap?
Healthpeak Properties, Inc.’s market cap is €13.46B.
When is Healthpeak Properties, Inc.’s upcoming earnings report date?
Healthpeak Properties, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 25 days.
How were Healthpeak Properties, Inc.’s earnings last quarter?
Healthpeak Properties, Inc. released its earnings results on May 05, 2026. The company reported €0.245 earnings per share for the quarter, beating the consensus estimate of €0.046 by €0.199.
Is Healthpeak Properties, Inc. overvalued?
According to Wall Street analysts Healthpeak Properties, Inc.’s price is currently Undervalued.
Does Healthpeak Properties, Inc. pay dividends?
Healthpeak Properties, Inc. does not currently pay dividends.
What is Healthpeak Properties, Inc.’s EPS estimate?
Healthpeak Properties, Inc.’s EPS estimate is 0.02.
How many shares outstanding does Healthpeak Properties, Inc. have?
Healthpeak Properties, Inc. has 689,419,700 shares outstanding.
What happened to Healthpeak Properties, Inc.’s price movement after its last earnings report?
Healthpeak Properties, Inc. reported an EPS of €0.245 in its last earnings report, beating expectations of €0.046. Following the earnings report the stock price went up 16.372%.
Which hedge fund is a major shareholder of Healthpeak Properties, Inc.?
Currently, no hedge funds are holding shares in DE:HC5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Healthpeak Properties Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€19.12 (30.16% Upside)
€19.12 (30.16% Upside)
Blogger Sentiment
Bullish
DE:HC5 Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €186.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.03%
12-Months-Change
Fundamentals
Return on Equity
2.88%
Trailing 12-Months
Asset Growth
9.09%
Trailing 12-Months
Company Description
Healthpeak Properties, Inc.
Healthpeak Properties, Inc. is an S&P 500 constituent operating as a fully integrated real estate investment trust (REIT). The firm is dedicated to the acquisition, management, and development of premier properties essential for both medical research and the provision of healthcare services.
HC5 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed constructive progress across multiple strategic fronts: outpatient medical fundamentals are strong (solid re-leasing spreads, high occupancy, low leasing costs), senior housing outperformance and the Janus Living IPO created clear value and near-term monetization optionality, and life science leasing momentum is building with targeted occupancy improvement guidance (+100 bps). Key near-term risks include lab rent pressure (quarterly re-leasing spreads softened), known vacates/expirations in life science that require conversion of pipeline, temporary earnings drag and public-company costs from the IPO, and refinancing/interest-rate headwinds. On balance, the company emphasized disciplined capital allocation (opportunistic acquisitions, recaps with Blackstone, share buybacks) and expects the recent transactions to be accretive over time.View all DE:HC5 earnings summariesHC5 Revenue Breakdown
76.41% Rental and related revenues
21.40% Resident fees and services
2.19% Interest income and other

HC5 Stock 12 Month Forecast
Average Price Target
€19.12
▲(30.16% Upside)
Technical Analysis
National Health Investors
―
Omega Healthcare
―
Sabra Healthcare REIT
―
―
Healthcare Realty Trust
―
Options Prices
Currently, No data available
---










